Research
Hormonal
GLP1:GIP:Gcg triple agonists (SAR441255) show potential for weight loss and neurological benefits, including improved memory in mouse models of TBI and Alzheimer's disease.
GLP1:GIP:Gcg triple agonists like SAR441255 show potential for weight loss and neurological benefits, including improved memory in animal models of TBI and Alzheimer's disease. However, human data is preliminary, and glycemic benefits may be inferior to dual agonists. These therapies are in early development.
LimitedSupportsLOW confidence
In addition to weight loss and improved glycemia, the GLP1:GIP:Gcg triple agonist therapies may also have neurological benefits. These include improved visual recognition and spatial memory in a mouse model of mild Traumatic Brain Injury (TBI), and improved working and reference memory (via testing in a radial maze) in a mouse model of Alzheimer’s disease [73,74].
Why this rating
Based on preliminary human studies and animal models, indicating early-stage research.
Source
Designer GLP1 poly-agonist peptides in the management of diabesity
Laura Statham et al. · Expert Review of Endocrinology & Metabolism · 2023
DOI 10.1080/17446651.2023.2204976
narrative_reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a GLP1:GIP dual agonist, provides superior glycemic and weight-loss efficacy compared to placebo, achieving >20% body weight loss in 57% of participants at the highest dose over 72 weeks.Good
- GLP1:Gcg dual agonists (Mazdutide and Cotadutide) show promise in weight loss and glycemic control, with additional benefits for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →